Eisai Patent-Cliff Exposure & CMS Drug Spending Portfolio

Eisai (Nutley, NJ): 7 reconciled FDA prescription therapies (0.6% 2025 to 2030 cliff risk), $1.14B 2024 CMS Part D & Medicaid spend, and 50 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterNutley, NJ
Reconciled FDA Portfolio Therapies7
2025 to 2030 Patent-Cliff Revenue Exposure0.6%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$1.14B
2024 Medicare Part D Spend$916.2M
2024 Medicaid Spend$221.0M
California HCAI SB 17 Filings50 WAC filings (max 23.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.